BIPROGY (8056) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
20 Oct, 2026Executive summary
Apr–Dec FYMar2024 revenue rose 12.6% YoY to ¥258.9B; operating profit increased 22.9% to ¥24.1B as system services and other businesses drove growth.
Orders and order backlogs increased YoY; full-year forecasts were revised upward following Q3 progress.
Financial highlights
Revenue was ¥258.9B vs ¥230.0B, up ¥28.9B or 12.6% YoY; gross profit was ¥68.7B vs ¥61.7B.
Operating profit was ¥24.1B vs ¥19.6B, up 22.9%; adjusted operating profit was ¥23.6B vs ¥19.3B, up 22.6%.
Profit attributable to owners of parent increased 33.8% to ¥18.2B from ¥13.6B.
SG&A expenses rose to ¥45.0B from ¥42.4B amid strengthened investments; gross profit growth absorbed the increase.
Outlook and guidance
FYMar2024 revenue forecast increased to ¥368.0B from ¥350.0B; operating profit to ¥34.0B from ¥32.5B; profit attributable to owners to ¥23.5B from ¥22.0B.
Adjusted operating profit forecast rose to ¥34.0B from ¥32.0B; full-year operating margin forecast is 9.2%.
Forecast revenue increase vs FYMar2023 is ¥28.1B, led by services (+¥24.5B) and products sales (+¥3.6B).
Latest events from BIPROGY
- Q1 operating profit rose 22% as revenue, orders, and backlog grew.8056
Q1 2024 - H1 revenue rose 11.8% and operating profit 21.9%; FY guidance stayed unchanged.8056
Q2 2024 - Strong DX demand lifted FYMar2024 results; growth investment supports FYMar2025 expansion.8056
Q4 2024 - Deferred product sales cut Q1 profit, while orders surged and FY2027 guidance stayed unchanged.8056
Q1 2027 - Q1 revenue and operating profit grew, with full-year guidance unchanged.8056
Q1 2025 - Revenue and operating profit rose, but net profit declined; full-year guidance was unchanged.8056
Q2 2025 - Revenue and orders grew, lifting the FY revenue forecast despite lower net profit.8056
Q3 2025 - Revenue and operating profit grew; FY2027 revenue target rose to ¥440bn.8056
Q4 2025 - Q1 revenue and profit grew; full-year guidance remains unchanged.8056
Q1 2026